Skip to main content

Cytokinetics Inc (CYTK) Stock

Cytokinetics Inc Stock Details, Movements and Public Alerts

Stock Details

Cytokinetics Inc (CYTK), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $60.16. Over the past 52 weeks, it has ranged between $29.31 and $64.13. This places the current price at 93.8% of its 52-week high and 105.3% above its 52-week low. Recent trading volume was recorded at 1,881,446. The 14-day Relative Strength Index (RSI) stands at 55.44, suggesting neutral conditions. The stock is currently trading above its 50-day moving average of $55.26 by 8.87%. Similarly, it is above its 200-day moving average of $42.78 by 40.63%. The MACD histogram is -0.45, indicating bearish momentum (MACD Line: 1.56, Signal Line: 2.01). There are currently 2 active alerts set for CYTK by users.

52-Week Range

$64.13 - $29.31

-6.19% from high · +105.25% from low

Avg Daily Volume

1,739,608

20-day average

100-day avg: 1,961,727

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

PEG Ratio

-0.42

Potentially undervalued

Price to Book

60.31

EV/EBITDA

-15.82

EPS (TTM)

-$6.29

Price to Sales

84.54

Beta

0.59

Less volatile than market

How is CYTK valued relative to its earnings and growth?
Valuation data is not available for this stock.
What is CYTK's risk profile compared to the market?
With a beta of 0.59, Cytokinetics Inc is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 60.31 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

-8613.00%

EBITDA

$-563,694,016

Return on Equity

-572.00%

Return on Assets

-24.90%

Revenue Growth (YoY)

318.10%

Earnings Growth (YoY)

0.00%

How profitable and efficient is CYTK's business model?
0 The operating margin of -8613.00% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -572.00% and ROA at -24.90%, the company achieves moderate returns on invested capital.
What are CYTK's recent growth trends?
Cytokinetics Inc's revenue grew by 318.10% year-over-year, representing robust expansion that significantly outpaces typical market growth rates. This strong top-line performance suggests the company is successfully capturing market share or benefiting from favorable industry trends.0 These growth metrics should be evaluated against BIOTECHNOLOGY industry averages for proper context.

Company Size & Market

Market Cap

$7.4B

Revenue (TTM)

$87.21M

Revenue/Share (TTM)

$0.73

Shares Outstanding

122.27M

Book Value/Share

-$4.34

Asset Type

Common Stock

What is CYTK's market capitalization and position?
Cytokinetics Inc has a market capitalization of $7.4B, classifying it as a mid-cap stock ($2B-$10B). Mid-caps often represent companies in their growth phase, offering higher growth potential than large-caps but with more stability than small-caps. They can be attractive takeover targets and may become tomorrow's large-caps. With 122.27M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
How does CYTK's price compare to its book value?
Cytokinetics Inc's book value per share is -$4.34, while the current stock price is $60.16, resulting in a price-to-book (P/B) ratio of -13.85. Trading below book value can indicate the market perceives challenges ahead, or it might represent a value opportunity if the assets are quality and earnings can recover. Value investors often screen for P/B ratios below 1.0. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$77.61

29.01% upside potential

Analyst Recommendations

Strong Buy

8

Buy

8

Hold

4

Sell

0

Strong Sell

0

How reliable are analyst predictions for CYTK?
20 analysts cover CYTK with 80% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $77.61 implies 29.0% upside, but targets are often adjusted to follow price moves rather than predict them.
What is the Wall Street consensus on CYTK?
Current analyst recommendations:8 Strong Buy, 8 Buy, 4 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Nov 8, 2025, 10:15 PM

Technical Indicators

RSI (14-day)

55.44

Neutral

50-Day Moving Average

$55.26

8.87% above MA-50

200-Day Moving Average

$42.78

40.63% above MA-200

MACD Line

1.56

MACD Signal

2.01

MACD Histogram

-0.45

Bearish

What does CYTK's RSI value tell investors?
The RSI (Relative Strength Index) for CYTK is currently 55.44, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
How should traders interpret CYTK's MACD and moving average crossovers?
MACD analysis shows the MACD line at 1.56 below the signal line at 2.01, with histogram at -0.45. This bearish crossover indicates downward pressure. The 50-day MA ($55.26) is above the 200-day MA ($42.78), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Nov 9, 2025, 12:39 AM

Active Alerts

Alert Condition
MA Breakout (Bearish)
Threshold
50 days
Created
Nov 8, 2025, 10:15 PM
Alert Condition
RSI Threshold Cross
Threshold
60
Created
Nov 8, 2025, 10:15 PM

Stay Ahead of the Market with Cytokinetics Inc Alerts

Set up price alerts for Cytokinetics Inc and get notified instantly when the price hits your target. Never miss an important price movement again.